Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03788772
Other study ID # APHP180016
Secondary ID 2018-A01934-51
Status Recruiting
Phase N/A
First received
Last updated
Start date July 15, 2019
Est. completion date July 15, 2022

Study information

Verified date July 2019
Source Assistance Publique - Hôpitaux de Paris
Contact Frédéric PENE, MD PhD
Phone +33 1 58 41 46 77
Email frederic.pene@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sepsis is a common life-threatening inflammatory response to infection and is the leading cause of death in the intensive care unit. Septic patients exhibit a complex immunosuppressive response affecting both innate and adaptive components of immunity, with a possible link to nosocomial infections. However, the molecular and cellular mechanisms resulting in secondary immunosuppression remain poorly understood, but may involve the antigen-presenting cells (APC, including dendritic cells and monocytes/macrophages) that link innate and adaptive immunity. Furthermore, the increasing phenotypic and functional heterogeneity of APC subsets raise the question of their respective role in sepsis. We propose to address the pathophysiologal role of APC using systems biology approaches in human sepsis.

The objective is to go from low- to high-resolution analysis of APC subset diversity and underlying molecular and functional features in sepsis. The global objective will be reached through:

1. Systematic description and phenotypic analysis of circulating APC subsets in sepsis

2. Association of APC subsets distribution, phenotype and function with severe sepsis physiopathology and relevant clinical outcomes (ICU-acquired infections and death)

3. High-resolution molecular profiling of circulating APC subsets using population level and single cell RNAseq.

To this aim, the investigator designed a prospective interventional study in order to collect blood samples at significant time points in patients with sepsis or septic shock (the population of interest) and relevant control subjects, either critically ill patients with non-septic acute circulatory failure or age-matched healthy subjects. The study's intervention is limited to additional blood samples. The risks and constraints are related to additional blood samples (maximum 120mL), which will be performed either from an arterial catheter when present in ICU patients, or from a venous puncture for patients without arterial catheters and for healthy volunteers.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date July 15, 2022
Est. primary completion date July 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. ICU patients with severe infections (Sepsis-3 definitions):

clinically or microbiologically documented infection and organ dysfunction graded as follows:

- Sepsis: increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more.

- Septic shock: vasopressor requirement to maintain a mean arterial pressure = 65mmHg and serum lactate level > 2 mmol/L in the absence of hypovolemia

2. ICU patients with non-septic acute circulatory failure:

- Cardiogenic shock: left ventricle systolic dysfunction (echocardiographic left ventricular ejection fraction < 45%) and the need of vasopressor (norepinephrine at any dose and inotropic support (dobutamine = 5 µg/kg/min or epinephrine at any dose) in the absence of patent infection.

- Severe hemorrhage: hypotension with acute blood loss requiring transfusion of at least four packed red cells within 24h and vasopressor support by norepinephrine or epinephrine at any dose.

3. Healthy controls:

- Blood donors

- Patients undergoing elective cataract surgery

Exclusion Criteria:

1. All ICU patients

- hematological malignancy (or significant history of bone marrow disease),

- HIV infection at any stage,

- any immunosuppressive drugs including corticosteroids = 0.5 mg/kg equivalent prednisone per day for more 7 days,

- anticancer chemotherapy or chemotherapy received during the last three months before inclusion

- bone marrow or solid organ transplantation,

- leucopenia (<1000/mm3) excepted if due to sepsis,

- pregnancy

- do-not-resuscitate order at ICU admission

- patients under legal protection regimen.

2. Healthy controls

- history of inflammatory disease

- hematological malignancy (or significant history of bone marrow disease),

- HIV infection at any stage,

- any immunosuppressive drugs including corticosteroids = 0.5 mg/kg equivalent prednisone per day for more 7 days,

- anticancer chemotherapy or immunotherapy received during the last three months before inclusion

- bone marrow or solid organ transplantation,

- pregnancy

- infectious symptoms within the previous month

- subjects under legal protection regimen

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Multiple blood sampling
ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)
Simple blood sampling
Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.

Locations

Country Name City State
France Cochin Hospital, AP-HP Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary ICU-acquired infections (nosocomial infections) Infections not present at the time of ICU admission and diagnosed at least after 48 hours in the ICU up to 3 months after the inclusion
Secondary In-hospital death date of death up to 3 months after the inclusion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3